Everything You Need to Know About Carbonic anhydrase inhibitors for Step 1

Carbonic anhydrase inhibitors (CAIs) are one of those Step 1 pharm topics that seem simple (“proximal tubule diuretics”) until you realize they show up everywhere—acid–base, kidney stones, altitude sickness, glaucoma, and even ventilator physiology. If you can connect the mechanism to the downstream electrolyte shifts, you’ll answer most questions in seconds.

Where Carbonic Anhydrase Works (and Why It Matters)

Carbonic anhydrase (CA) catalyzes the reversible reaction:

$CO_2 + H_2O \leftrightarrow H_2CO_3 \leftrightarrow H^+ + HCO_3^-$

There are two clinically relevant locations:

Proximal convoluted tubule (PCT)
- Luminal (brush border) CA helps reclaim filtered bicarbonate by converting luminal $H_2CO_3 \to CO_2 + H_2O$ , allowing $CO_2$ to diffuse into the cell.
- Cytosolic CA regenerates intracellular $H^+$ (to fuel the Na/H exchanger) and $HCO_3^-$ (to return to blood).
Eye (ciliary body)
- CA helps generate aqueous humor (via $HCO_3^-$ -linked fluid secretion).
Choroid plexus
- CA participates in CSF production.
Type A intercalated cells (collecting duct)
- Less commonly emphasized, but CA supports acid secretion physiology.

Step takeaway: If you inhibit CA in the PCT, you lose bicarbonate reabsorption, which drags sodium and water with it—and you change urinary pH in a way that predisposes to stones.

The Drugs (Know These Cold)

Common carbonic anhydrase inhibitors

Acetazolamide (classic, systemic)
Dorzolamide, Brinzolamide (topical ophthalmic)

First Aid cross-reference: Renal—Diuretics (CA inhibitors: acetazolamide; adverse effect: calcium phosphate stones; metabolic acidosis; hypokalemia; sulfa allergy).

Mechanism of Action (PCT): The Full Chain Reaction

What CAIs do

Inhibit carbonic anhydrase → ↓ $H^+$ generation in PCT cell
↓ activity of Na $^+$ /H $^+$ exchanger (NHE3) (because less intracellular $H^+$ available to secrete)
↓ NaHCO $_3$ reabsorption
↑ urinary bicarbonate → alkalinized urine
↓ plasma bicarbonate → non–anion gap metabolic acidosis (NAGMA)

Why hypokalemia can happen

Even though CAIs act in the PCT, extra Na $^+$ delivery to the collecting duct increases:

Na $^+$ reabsorption through ENaC
K $^+$ secretion by principal cells

Net: hypokalemia is a classic board-relevant effect (often framed as “diuretics cause hypokalemia,” with the CAI nuance being mild diuresis but still K $^+$ loss).

Expected Acid–Base Pattern (Classic Question Stem)

Carbonic anhydrase inhibitor acid–base effects

Serum: ↓ $HCO_3^-$ → metabolic acidosis
Anion gap: typically normal (hyperchloremic/NAGMA)
Urine: ↑ $HCO_3^-$ excretion → urine pH increases (alkaline)

High-yield comparison:

Proximal RTA (Type 2): impaired $HCO_3^-$ reabsorption → NAGMA, can be caused by acetazolamide.
Distal RTA (Type 1): impaired $H^+$ secretion → alkaline urine + stones, but the mechanism differs.

Clinical Uses (Think “Altitude, Eye, ICP, Alkaline Urine”)

1) Glaucoma

Decreases aqueous humor production → ↓ intraocular pressure
Acetazolamide (systemic) or dorzolamide/brinzolamide (topical)

2) Idiopathic intracranial hypertension (pseudotumor cerebri)

↓ CSF production by choroid plexus CA inhibition
Helps reduce papilledema symptoms

3) Acute mountain sickness (altitude sickness)

This is a favorite because it tests physiology rather than pure memorization:

CAIs cause metabolic acidosis
The mild acidosis stimulates ventilation (hyperventilation), helping compensate for hypoxemia at altitude

4) Metabolic alkalosis (selected cases)

By promoting bicarbonate loss, acetazolamide can help correct metabolic alkalosis (e.g., diuretic-induced alkalosis or ventilated patients with alkalemia—context matters)

5) Urine alkalinization (rarely tested nuance)

Because CAIs alkalinize urine, they can theoretically help with uric acid stones (which dissolve better in alkaline urine). But on exams, CAIs are more famously linked to calcium phosphate stones.

Adverse Effects: The “CAI Toxicity Bundle”

The high-yield list

Metabolic acidosis (NAGMA)
Hypokalemia
Calcium phosphate kidney stones (from alkaline urine)
Paresthesias (tingling; common in real life and sometimes tested)
Sulfonamide allergy (acetazolamide is a sulfonamide derivative)
Hyperammonemia risk (important in cirrhosis; can worsen hepatic encephalopathy)

Why CAIs cause kidney stones (pathophysiology)

CA inhibition → alkaline urine favors precipitation of:

Calcium phosphate stones

Contrast this with:

Loop diuretics → hypercalciuria → calcium-based stones risk (different mechanism, not urine alkalinization)
Thiazides → decrease urinary calcium → used to prevent calcium oxalate stones

Carbonic Anhydrase Inhibitors & Renal Stones: Board-Style Integration

Stone type linked to CAIs

Calcium phosphate stones (radiopaque)

Classic vignette clues

Patient on acetazolamide for altitude sickness or glaucoma
Develops flank pain, hematuria
Urine pH elevated
Possible concurrent metabolic acidosis

One-table stone review (Step 1-friendly)

Stone Type	Radiology	Urine pH Tendency	Classic Associations
Calcium oxalate / calcium phosphate	Radiopaque	Oxalate: variable; Phosphate: alkaline	Acetazolamide, hypercalciuria, ethylene glycol (oxalate), Vit C excess
Uric acid	Radiolucent	Acidic	Gout, tumor lysis, myeloproliferative disorders
Struvite (MgNH $_4$ PO $_4$ )	Radiopaque	Alkaline	Urease+ (Proteus, Klebsiella), staghorn calculi
Cystine	Faintly radiopaque	Acidic	COLA aminoaciduria (cystinuria)

High-yield twist: Both struvite and calcium phosphate are linked to alkaline urine, but struvite is infection/urease-driven; calcium phosphate is more about alkalinization + calcium/phosphate precipitation (including from CAIs).

Diagnosis/Recognition on Exams (What They Actually Ask)

You’re usually identifying CAI effects from patterns:

Lab pattern: NAGMA + hypokalemia + alkaline urine
Clinical context: glaucoma/altitude/IIH treatment
Complication: kidney stones

Common question prompts

“Which diuretic alkalinizes urine?”
“Which drug can cause a proximal renal tubular acidosis picture?”
“Drug used for altitude sickness—what acid–base change occurs?”
“Patient develops kidney stones after starting a medication for glaucoma—mechanism?”

Treatment Pearls (and What to Do About Side Effects)

If the question is “what do you do next?”

It depends on what they’re testing:

Altitude sickness prophylaxis/treatment: acetazolamide (unless contraindicated)
Glaucoma: topical dorzolamide/brinzolamide, or systemic acetazolamide in some cases
IIH: acetazolamide as first-line pharmacologic therapy
CAI-induced metabolic acidosis: stop drug if severe; supportive care; address electrolytes
Stone prevention: avoid prolonged use when possible; monitor; consider risk factors (history of stones)

Contraindication-style associations (high yield)

Sulfa allergy → avoid acetazolamide (testable even though true cross-reactivity nuances exist clinically)
Cirrhosis → acetazolamide may worsen hyperammonemia → hepatic encephalopathy

First Aid–Style Rapid Review (What to Memorize)

Carbonic anhydrase inhibitors = acetazolamide, dorzolamide, brinzolamide

MOA: inhibit CA in PCT → ↓ $HCO_3^-$ reabsorption → alkaline urine, metabolic acidosis
Uses: glaucoma, altitude sickness, IIH, metabolic alkalosis (select)
AEs: kidney stones (calcium phosphate), hypokalemia, sulfa allergy, paresthesias

Ultra–High-Yield Mini Quiz (Self-check)

Urine pH after acetazolamide? → Up (alkaline)
Acid–base status? → Normal anion gap metabolic acidosis
Stone type risk? → Calcium phosphate
Why helps at altitude? → Metabolic acidosis → stimulates ventilation
Major electrolyte issue? → Hypokalemia